NCT02322086View on ClinicalTrials.gov

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2017

Conditions
Psoriasis
Interventions
DRUG

Topical Rose Bengal, 0.005%

Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).

Trial Locations (3)

27516

University of North Carolina School of Medicine, Chapel Hill

33144

International Dermatology Research, Miami

78759

DermResearch Inc., Austin

Sponsors
All Listed Sponsors
lead

Provectus Pharmaceuticals

INDUSTRY